R&D Drug repositioning to bring forgotten assets from shelves to... A problem very rarely spoken about is the treatments that are promising, but are not developed further.
R&D Sponsored Tips for on-time tech transfers that stay on budget When it comes to life sciences manufacturing, there's nothing quite so daunting as a tech transfer - moving a product from development to commercialisation, or to a new facility or CDMO, pr
R&D Sponsored SK Life Science Leverages Smart, Efficient Solutions Across ... When SK Life Science began, it tapped into healthcare providers, patients, and scientists t
R&D Opportunity costs of gene therapies. Where do we go from her... Over 30 gene therapies have received regulatory approval.
Sales & Marketing How data is critical to commercialising drugs for rare disea... Orphan drugs are designed to treat rare diseases, but “rare” is a relative term.
Sales & Marketing Why commercialisation is the next frontier for digital innov... In March, Cigna and its pharmacy benefit manager subsidiary Evernorth announced plans to limit spending increases on GLP-1 drugs at 15% per year.
News Agios mulls early FDA filing for sickle cell therapy Agios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
